FBT News and Press, First Trust Amex Biotech Index Fund From 01/20/20

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...

Question: Why are there so many ETFs? Answer: ETF providers tend to make lots of money on each ETF so they create more products to sell. The large number of ETFs has little to do with serving your best interests. We leverage our data to identify three red flags you can use to avoid the w...

The Healthcare sector ranks seventh out of the 11 sectors as detailed in our Q4'19 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked fourth. It gets our Neutral rating, which is based on an aggregation of ratings of the 351 stocks in the Healthca...

Photo Source: REUTERS/Brendan McDermid. A Wall St. street sign is seen near the New York Stock Exchange, September 17, 2019. For the fifth month in a row, investors were net purchasers of mutual fund assets, injecting $57.1 billion into the conventional funds business (excluding ETFs, whic...

Question: Why are there so many ETFs? Answer: ETF providers tend to make lots of money on each ETF so they create more products to sell. The large number of ETFs has little to do with serving your best interests. Below are three red flags you can use to avoid the worst ETFs: 1. Inadeq...

Aprea Therapeutics (NASDAQ: APRE ) opens for trading after raising the size of its IPO to 5.67M shares from 5M and pricing its IPO at $15 , the mid‐point of the $14‐$16 expected range. More news on: Aprea Therapeutics, Monopar Therapeutics, ADC Therapeutics SA, Healthcare st...

Biotechnology stocks get a lot of attention. It's easy to be enamored with the curing of disease, and the financial results that could follow the successful introduction of a new treatment can be game-changing. But, alas, it isn't as simple as picking a few promising names with lucrative treatm...

(Source - Pexels/Pixbay ) It is widely believed that the Healthcare sector is a safe sector in a recessionary environment because "people always need medical treatment." While that is historically true, it seems that many investors are underweighting the substantial risks in the sector. H...

Bloomberg reports that Evercore ISI's Mark Schoenebaum, a highly regarded biotech analyst, has died from undisclosed causes. More news on: Health Care Select Sect SPDR ETF, SPDR Biotech ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, News on ETFs, Read more ...